Loading data for BCAB — first visit, this takes a few seconds.
BioAtla Inc. (BCAB)
NasdaqCM: BCAB
· Real-Time Price · USD
3.56
+0.32 (9.88%)
At close: Aug 24, 2026, 8:00 PM
3.18
-2.99%
Pre-market: 6:06 AM
The price, the headline numbers and the latest news, in one place.
BioAtla Inc. (BCAB) Stock Price, Analysis & Data
9.88% (1D)
No data available
| Bid | 2.86 |
| Market Cap | 5.46M |
| Revenue (ttm) | 8.5M |
| Net Income (ttm) | -31.45M |
| 0.76 | |
| -25.86 | |
| n/a | |
| -2.45 | |
| P/B (ttm) | -0.15 |
| P/S (ttm) | 0.64 |
| Earnings Date | Nov 12, 2026 |
| Ask | 4.58 |
| Volume | 318,104 |
| Avg. Volume (20D) | 59,262 |
| Open | 3.27 |
| Previous Close | 3.24 |
| Day's Range | 3.10 - 4.00 |
| 52-Week Range | 2.81 - 71.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BCAB
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to trea...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 41
Stock Exchange NasdaqCM
Ticker Symbol BCAB
Website https://www.bioatla.com
Financial Performance
In 2025, BioAtla's revenue was 2M, a decrease of -81.82% compared to the previous year's 11M. Earnings were -59.61M, a decrease of -14.57%.
Financial StatementsEarnings Surprise
BioAtla has released their quarterly earnings on Nov 13, 2025:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -13.5 exceeds estimates by 1.33, with -22.73% YoY decline.
BioAtla Inc. is scheduled to release its earnings on Nov 12, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
